Boston, MA 03/11/2014 (wallstreetpr) – Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) is working on technology that will detect cancer at an early stage. Successful treatment of cancer depends heavily on the stage in which it is detected.
MicroRNA Diagnosis:
One of the drawbacks of cancer detection is that it is detected very late. The success rate of treatment is dependent on the stage in which it is detected, apart from other factors. As the symptoms are many times associated with other illnesses, cancer detection becomes difficult at an early stage. Many companies including Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) have been working on this issue. Rosetta is not concentrating on cancer alone; the molecular diagnostics company is also focusing on molecular testing for other diseases.
Though many competing companies are also actively engaged in the medical diagnostics field, the company has many positives on its side. Very few companies are engaged in developing this technique and if the company succeeds, it can reap rich dividends.
The Market Size:
The market size is very huge. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) has currently four cancer tests, the cancer origin test, the kidney cancer test, the mesothelioma test and the lung cancer test. It is estimated that with a proper marketing strategy in place, the company can draw revenues of $125 million by 2020.
Apart from the cancer tests, the company is also targeting other illnesses. It received a boost following the publication of a study for prognosis of chronic heart failure in patients with atrial fibrillation. Such patients have a poor prognosis. It has firmed up plans to launch a test for such diseases by 2017.
Apart from these, the company has a strong library of Intellectual Property. It has developed a strong and diversified portfolio that covers a large portion of human and viral microRNAs. It also has filed a number of patent applications that protect the composition of matter as well as its extraction and diagnostics methods. This will allow the company to monetize its technology in the future.
